APOBEC3G: A double agent in defense

Trends in Biochemical Sciences

Volumn 36, Issue 5, 2011, Pages 239-244

  Smith, Harold C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DEAMINASE; RIBONUCLEOPROTEIN; SINGLE STRANDED DNA; SUPPRESSOR OF CYTOKINE SIGNALING; VIF PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CATALYSIS; COMPLEX FORMATION; DIMERIZATION; HOST RESISTANCE; HUMAN; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN RNA BINDING; REVERSE TRANSCRIPTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; STOP CODON; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS REPLICATION;

CYTIDINE DEAMINASE; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; RNA; TIME FACTORS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 79955651515     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2010.12.003     Document Type: Review

References (80)

1. Wedekind J.E., et al. Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 2003, 19:207-216.
2. Smith H.C. The APOBEC1 Paradigm for Mammalian Cytidine Deaminases that Edit DNA and RNA 2009, Landes bioScience.
3. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
4. Yu Y., et al. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 2004, 18:2867-2872.
5. Stopak K., et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 2003, 12:591-601.
6. Zhang H., et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424:94-98.
7. Mangeat B., et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103.
8. Yu Q., et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11:435-442.
9. Simon V., et al. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 2005, 1:e6.
10. Pace C., et al. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 2006, 80:9259-9269.
11. Sato K.I., et al. Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J. Virol. 2010, 84:9546-9556.
12. Simon J.H., Malim M.H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 1996, 70:5297-5305.
13. Gaddis N.C., et al. Comprehensive investigation of the molecular defect in Vif-deficient human immunodeficiency virus type 1 virions. J. Virol. 2003, 77:5810-5820.
14. Shindo K., et al. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 2003, 278:44412-44416.
15. Li J., et al. Functional domains of APOBEC3G required for antiviral activity. J. Cell Biochem. 2004, 92:560-572.
16. Browne E.P., et al. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 2009, 387:313-321.
17. Soros V.B., et al. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 2007, 3:e15.
18. Goila-Gaur R., et al. Differential sensitivity of "old" versus "new" APOBEC3G to human immunodeficiency virus type 1 vif. J. Virol. 2009, 83:1156-1160.
19. Cen S., et al. Small molecular inhibitors for HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 2010, 285:16546-16552.
20. Nathans R., et al. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 2008, 26:1187-1192.
21. Miller J.H., et al. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 2007, 4:81.
22. Mikl M.C., et al. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell Biol. 2005, 25:7270-7277.
23. Huang J., et al. Derepression of microRNA-mediated protein translation inhibition by apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G) and its family members. J. Biol. Chem. 2007, 282:33632-33640.
24. Muckenfuss H., et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 2006, 281:22161-22172.
25. Chiu Y.L., et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:15588-15593.
26. Esnault C., et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005, 433:430-433.
27. Niewiadomska A.M., et al. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association. J. Virol. 2007, 81:9577-9583.
28. Sawyer S.L., et al. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004, 2:E275.
29. Russell R.A., Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 2007, 81:8201-8210.
30. Mariani R., et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31.
31. Xu H., et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:5652-5657.
32. Mangeat B., et al. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 2004, 279:14481-14483.
33. Bogerd H.P., et al. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3770-3774.
34. Hu C., et al. The HIV-1 central polypurine tract functions as a second line of defense against APOBEC3G/F. J. Virol. 2010, 84:11981-11993.
35. Chiu Y.L., et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005, 435:108-114.
36. Chiu Y.L., et al. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2010, 466:276.
37. Kamata M., et al. Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathog. 2009, 5:e1000342.
38. Santoni de Sio F.R., Trono D. APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. PLoS One 2009, 4:e6571.
39. Pillai S.K., et al. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 2008, 5:1-8.
40. Albin J.H., et al. Long-term restriction by APOBEC3F selects human immunodeficiency virus type 1 variants with restored Vif function. J. Virol. 2010, 84:10209-10219.
41. Kim E.-Y.B., et al. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J. Virol. 2010, 84:10402-10405.
42. Sadler H.S., et al. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 2010, 84:7396-7404.
43. Iwatani Y., et al. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 2006, 80:5992-6002.
44. Chelico L., et al. APOBEC3G DNA deaminase acts processively 3' → 5' on single-stranded DNA. Nat. Struct. Mol. Biol. 2006, 13:392-399.
45. Chelico L., et al. A structural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3G. J. Biol. Chem. 2010, 285:16195-16205.
46. Yu X., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
47. Mehle A., et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 2004, 279:7792-7798.
48. Huthoff H., Malim M.H. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 2007, 81:3807-3815.
49. Zhang L., et al. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 2008, 370:113-121.
50. Santa-Marta M., et al. HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 2005, 280:8765-8775.
51. Schrofelbauer B., et al. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 2006, 80:5984-5991.
52. Chen G., et al. A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 2009, 83:8674-8682.
53. Tian C., et al. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 2006, 80:3112-3115.
54. Mehle A., et al. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 2004, 18:2861-2866.
55. Wolfe L.S., et al. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J. Virol. 2010, 84:7135-7139.
56. Hache G., et al. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 2005, 280:10920-10924.
57. Navarro F., et al. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333:374-386.
58. Newman E.N., et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15:166-170.
59. Bishop K.N., et al. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 2006, 80:8450-8458.
60. Khan M.A., et al. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 2007, 4:48.
61. Svarovskaia E.S., et al. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 2004, 279:35822-35828.
62. Guo F., et al. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 2007, 81:11322-11331.
63. Li X.Y., et al. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 2007, 282:32065-32074.
64. Bishop K.N., et al. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008, 4:e1000231.
65. Mbisa J.B., et al. HIV-1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 2007, 81:7099-7110.
66. Luo K., et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 2007, 81:7238-7248.
67. Alce T.M., Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 2004, 279:34083-34086.
68. Cen S., et al. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 2004, 279:33177-33184.
69. Bogerd H.P., Cullen B.R. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 2008, 14:1228-1236.
70. Huthoff H., et al. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 2009, 5:e1000330.
71. Wang T., et al. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J. Virol. 2007, 81:13112-13124.
72. Bach D., et al. Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 2008, 5:54.
73. Salter J.D., et al. A hydrodynamic analysis of APOBEC3G reveals a monomer-dimer-tetramer self-association that has implications for anti-HIV function. Biochemistry 2009, 48:10685-10687.
74. Wedekind J.E., et al. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem. 2006, 281:38122-38126.
75. Kreisberg J.F., et al. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 2006, 203:865-870.
76. Wichroski M.J., et al. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2006, 2:e41.
77. Stopak K.S., et al. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 2007, 282:3539-3546.
78. Kozak S.L., et al. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 2006, 281:29105-29119.
79. Gallois-Montbrun S., et al. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 2007, 81:2165-2178.
80. Vetter M.L., D'Aquila R.T. Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells. J. Virol. 2009, 83:8646-8654.